Valneva Se ADR (VALN) Stock Price, Quote & News

Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-a...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 2 28 07 37 10

Fax: 33 2 28 07 37 11

Website: valneva.com

Address:

6 rue Alain Bombard, Saint-Herblain, France

Siuolman58 Sep. 10 at 11:26 AM

$VALN This is the right one to buy! The future looks promising in the Lyme especially !

1 · Reply

Thestocktraderhubzee Sep. 3 at 9:19 AM

WATCHLIST SEP 03 2025 $VALN Valneva Lyme Vaccine Candidate VLA15 Demonstrates Strong Anamnestic Response And Favorable Safety Profile After Third Yearly Booster Dose $HLNE Hamilton Lane Expands Evergreen Platform With Global Private Secondary Fund Targeting Diversified Mature Private Equity Investments $CDE Walker Lane Resources Ltd. Announces the Commencement of Drilling by Coeur Silvertip Holdings on its Silverknife Property, British Columbia $XPER Xperi's TiVo One Advertising Platform Reaches Over 4 Million Monthly Active Users And Expands TiVo OS to 40+ Countries $AON Financial Times Reported Earlier, Aon Is Nearing A Sale Of Its NFP Wealth Business To Madison Dearborn For Nearly $3B

0 · Reply

TheCheeseWrangler Sep. 3 at 5:22 AM

$VALN https://valneva.com/press-release/valneva-reports-further-positive-phase-2-safety-and-immunogenicity-results-for-lyme-disease-vaccine-candidate/

0 · Reply

Explorer2234 Aug. 26 at 10:16 AM

$VALN Waiting for entry. If and when Lyme vaccine is approved the stock will skyrocket.

1 · Reply

LittleMy Aug. 25 at 9:12 PM

$VALN buying back some of what I sold above $12

0 · Reply

StocktwitsNews Aug. 25 at 5:37 PM

Valneva Stock Tumbles 19% After FDA Suspension Of Ixchiq License In US, Wall Street Divided On The Impact $VALN https://stocktwits.com/news/equity/markets/valneva-stock-tumbles-after-us-fda-suspension-of-ixchiq-license/chssvsiRdSe

0 · Reply

buzzkiller Aug. 25 at 4:33 PM

$VALN check out that volume -- dropping dead weight

0 · Reply

lipmaz Aug. 25 at 4:23 PM

$VALN just when we were starting to get some momentum

0 · Reply

ajmore Aug. 25 at 3:59 PM

$VALN are you keeping an eye on the new appointment that will lead the covid task force! He called mrna vaccines unsafe. This is actually good news for Valneva! the safest conventional covid shot. And more reasons for $PFE to make a move for valneva! Buy the dip.

1 · Reply

Papusa Aug. 25 at 3:33 PM

$VALN this company has so bad luck like no other. Maybe one day they will get bought by Pfizer

2 · Reply

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

Aug 25, 2025, 12:02 PM EDT - 22 days ago

Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday

KDP VENU

Aug 25, 2025, 10:43 AM EDT - 22 days ago

Johnson Fistel Investigates Valneva Following FDA Suspension

Aug 25, 2025, 10:29 AM EDT - 22 days ago

Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US

Aug 25, 2025, 1:16 AM EDT - 23 days ago

FDA suspends Valneva's chikungunya vaccine license in the U.S.

Aug 25, 2025, 1:00 AM EDT - 23 days ago

Valneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.

Aug 18, 2025, 1:00 AM EDT - 4 weeks ago

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Aug 12, 2025, 3:20 PM EDT - 5 weeks ago

Valneva SE (VALN) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 1:00 AM EDT - 5 weeks ago

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Aug 7, 2025, 1:18 AM EDT - 5 weeks ago

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

Jul 29, 2025, 10:00 AM EDT - 7 weeks ago

AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate

Jul 11, 2025, 11:35 AM EDT - 2 months ago

Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

Jul 11, 2025, 8:18 AM EDT - 2 months ago

Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults

Jun 26, 2025, 1:00 AM EDT - 2 months ago

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

Jun 25, 2025, 11:45 AM EDT - 2 months ago

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

Jun 9, 2025, 10:29 AM EDT - 3 months ago

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

Jun 5, 2025, 11:45 AM EDT - 3 months ago

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

Jun 4, 2025, 1:00 AM EDT - 3 months ago

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

May 26, 2025, 11:30 AM EDT - 4 months ago

Valneva to Participate at U.S. and European Investor Conferences in June

May 12, 2025, 1:00 AM EDT - 4 months ago

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

May 9, 2025, 9:47 AM EDT - 4 months ago

Valneva SE (VALN) Q1 2025 Earnings Call Transcript

May 8, 2025, 12:30 AM EDT - 4 months ago

Valneva SE: Still Undervalued Travel Vaccine Bet With Robust 2025 Guidance

May 7, 2025, 11:45 AM EDT - 4 months ago

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

May 7, 2025, 8:40 AM EDT - 4 months ago

Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people

May 7, 2025, 1:00 AM EDT - 4 months ago

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Apr 26, 2025, 1:10 PM EDT - 5 months ago

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Apr 18, 2025, 4:00 AM EDT - 5 months ago

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Apr 16, 2025, 11:45 AM EDT - 5 months ago

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Apr 14, 2025, 2:28 PM EDT - 5 months ago

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine

Apr 14, 2025, 11:45 AM EDT - 5 months ago

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

Apr 9, 2025, 1:00 AM EDT - 5 months ago

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2

Apr 7, 2025, 9:33 AM EDT - 5 months ago

VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm

Apr 3, 2025, 11:45 AM EDT - 5 months ago

Valneva SE Shareholding Declaration - March 2025

Apr 1, 2025, 11:45 AM EDT - 6 months ago

Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

Mar 31, 2025, 1:00 AM EDT - 6 months ago

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

Mar 26, 2025, 1:00 PM EDT - 6 months ago

Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program

Mar 25, 2025, 2:00 AM EDT - 6 months ago

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F

Mar 24, 2025, 2:00 AM EDT - 6 months ago

Valneva Responds to French Government's Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

Mar 20, 2025, 8:00 PM EDT - 6 months ago

Valneva SE (VALN) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation

Mar 20, 2025, 2:00 AM EDT - 6 months ago

Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook

Mar 19, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out

Mar 18, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation

Mar 17, 2025, 10:00 AM EDT - 6 months ago

Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Mar 16, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Shareholders to Inquire about Securities Investigation

Mar 14, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect

Mar 13, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Stockholders to Inquire about Securities Investigation

Siuolman58 Sep. 10 at 11:26 AM

$VALN This is the right one to buy! The future looks promising in the Lyme especially !

1 · Reply

Thestocktraderhubzee Sep. 3 at 9:19 AM

0 · Reply

TheCheeseWrangler Sep. 3 at 5:22 AM

$VALN https://valneva.com/press-release/valneva-reports-further-positive-phase-2-safety-and-immunogenicity-results-for-lyme-disease-vaccine-candidate/

0 · Reply

Explorer2234 Aug. 26 at 10:16 AM

$VALN Waiting for entry. If and when Lyme vaccine is approved the stock will skyrocket.

1 · Reply

LittleMy Aug. 25 at 9:12 PM

$VALN buying back some of what I sold above $12

0 · Reply

StocktwitsNews Aug. 25 at 5:37 PM

0 · Reply

buzzkiller Aug. 25 at 4:33 PM

$VALN check out that volume -- dropping dead weight

0 · Reply

lipmaz Aug. 25 at 4:23 PM

$VALN just when we were starting to get some momentum

0 · Reply

ajmore Aug. 25 at 3:59 PM

1 · Reply

Papusa Aug. 25 at 3:33 PM

$VALN this company has so bad luck like no other. Maybe one day they will get bought by Pfizer

2 · Reply

nroberts7 Aug. 25 at 3:19 PM

$VALN stock didnt react as badly as i thought! Trimming even more profits here to de-risk the position

0 · Reply

stockanalysis_ Aug. 25 at 1:50 PM

Losers Today: $EPIX $MODV $EEIQ $VALN $NXL Bookmark this screener here: https://stockanalysis.com/markets/losers/?ref=saveontrading

0 · Reply

DARKP00L Aug. 25 at 1:01 PM

$VALN 08:55 on Aug. 25 2025 FDA Update On The Safety Of Ixchiq (Chikungunya Vaccine, Live). FDA Suspends Biologics License: FDA Safety Communication #tradeideas

0 · Reply

stockanalysis_ Aug. 25 at 12:42 PM

Premarket Losers: $EPIX $MODV $DRIO $VALN $SHFS Save this screener here: https://stockanalysis.com/markets/premarket/losers/?ref=saveontrading

0 · Reply

OpenOutcrier Aug. 25 at 12:33 PM

$VALN (-20.5% pre) Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® In the U.S. https://ooc.bz/l/75049

0 · Reply

buzzkiller Aug. 25 at 11:01 AM

$VALN thank you RFK and pals for one last golden buying opportunity.

0 · Reply

Rampageusa Aug. 25 at 10:25 AM

$VALN short ad much as you can till further news from FDA. we can see drop till 5$ from currnt price.

0 · Reply

ajmore Aug. 25 at 7:57 AM

$VALN Kempen analyst "we see negative price reaction today as an attractive entry point", analysts adds that chikungya is only a minor reason to invest in Valneva! I am still in view that valneva and fda will agree on resumption of the vaccine with a clearer label on age and underlying health issues.

2 · Reply

AVXLIMMINENTZERO Aug. 25 at 7:44 AM

$VALN

0 · Reply

ajmore Aug. 25 at 6:07 AM

$VALN Valneva maintaining financial guidance. -The sae events are related to underlying health issues. -The events are consistent with data from trials. -The warning label, which every drug or vaccine usually have, relates to these underlying health issues.

0 · Reply

Boonkers Aug. 25 at 5:26 AM

$VALN https://valneva.com/press-release/valneva-announces-fdas-decision-to-suspend-license-of-chikungunya-vaccine-ixchiq-in-the-u-s/

0 · Reply

TheCheeseWrangler Aug. 25 at 5:06 AM

$VALN https://valneva.com/press-release/valneva-announces-fdas-decision-to-suspend-license-of-chikungunya-vaccine-ixchiq-in-the-u-s/

0 · Reply

Market Cap	767.33M
Revenue (ttm)	183.50M
Net Income (ttm)	-13.25M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7.22%
Debt to Equity Ratio	0.90

Volume	26,200
Avg Vol	92,852
Day's Range	N/A - N/A
Shares Out	85.93M
Stochastic %K	49%
Beta	1.78
Analysts	Strong Sell
Price Target	$13.28